Results 81 to 90 of about 49,940 (198)

Emerging Roles of PSTPIP2 in Autoimmunity: From Mechanism to Therapeutic Implications

Immunology, EarlyView.
PSTPIP2 acts as a key brake on myeloid inflammation by suppressing IL‐1β‐driven signalling, macrophage dysregulation and inflammation‐associated bone remodelling. Its emerging roles in CRMO/CMO, rheumatoid arthritis, SAPHO syndrome and bullous pemphigoid support its potential as a biomarker and therapeutic target.
Erdong Zhang, Fengyu Liu, Yongle Wei, Guoqiang Li, Liujie Zheng, Lin Jin, Feng Luan, Yingze Zhang, Ling Wang, Zhiyong Hou   +9 more
wiley   +1 more source

International consensus on dose reduction of biologics for patients with psoriasis: The DR. Delphi study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Dermatologists worldwide reached consensus on criteria for dose reduction (DR) of biologics for psoriasis resulting in a DR algorithm for adalimumab, etanercept and ustekinumab. DR of IL‐17 and IL‐23 inhibitors was deemed feasible as well. This first international consensus provides essential information for uptake of biologic DR for psoriasis globally.
C. A. M. van Riel, W.‐H. Boehncke, J. L. W. Lambert, P. I. Spuls, L. S. van der Schoot, I. van Ee, E. M. G. J. de Jong, J. M. P. A. van den Reek, on behalf of the eDelphi consortium, M. Elkalioby, L. Fianen, L. Linhares Leite, C. Boesjes, S. Mahil, M. Franco, F. Valenzuela, C. Chaiyabutr, M. A. Lorna, F. Frez, O. Zargari, T. Hillary, H. Oon, L. Skov, M. Gupta, E. Sotiriou, N. Nguyen Loft, R. Ceovic, K. M. G. Klaassen, J. Wikström, C. Zachariae, P. Asawanonda, R. Vender, A. Carvalho, J. Song, C. Lan, J.‐T. Maul, D. Jullien, B. Hidalgo‐Matlock, A. Duvetorp, M. Gkini, D. Ioannidis, W. Veldkamp, J. Hugo, J. Barboza, A. Carugno, A. Londoño‐García, L. Schneller‐Pavelescu Apetrei, M. Ferran, F. Lafuente Urrez, N. Merino, M. Llamas Velasco, L. Puig, M. Bourcier, M. Perez Ferriols, T. Leonidze, D. Armijo, A. Eylenbosch, M. B. A. van Doorn, P. P. M. van Lumig, P. Ghislain, A. Nast, S. Lanssens, E. Sonkoly, D. J. Hijnen, E. M. Baerveldt, P. Gisondi, M. Tjioe, I. Haeck, K. Agerberg, Y. Okubo   +69 more
wiley   +1 more source

Impact of methotrexate and etanercept drugs on serum levels of soluble toll-like receptor-2 in Iraqi patients with rheumatoid arthritis

Egyptian Rheumatology and Rehabilitation
Background Methotrexate and Etanercept are common treatment strategies for rheumatoid arthritis (RA) and are classified as conventional synthetic and biologic disease-modifying antirheumatic drugs respectively.
Muna R. Hameed, Faiq I. Gorial, Fayhaa M. khaleel   +2 more
doaj   +1 more source

Mechanism and Efficacy of Etanercept in Treating Autoimmune-like Manifestations of Coronavirus Disease 2019 in elderly individuals

Immunobiology
During the COVID-19 pandemic, extensive research focused on universal treatments, but few studies addressed treatment regimens for elderly patients. This study aimed to evaluate the effects of etanercept, a TNF inhibitor, in elderly individuals with ...
Lizhong Zhang, Hongyi Li, Lei Shi, Jie Geng, Haojun Zhang, Haoran Chen, Peng Zhao, Yang Xiao, Jinqi Lu, Zhilun Li, Hongbin Pu, Chuandong Hou, Chenghui Li, Chumeng Gao, Xia Song, Zhuocheng Bao, Bing Zhai, Bo Guo, Bo Yang, Xuechun Lu, Qi Yu   +20 more
doaj   +1 more source

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This international, multicentre real‐world study of 148 patients’ documents treatment‐associated, bidirectional phenotype switching between psoriasis and atopic dermatitis. Psoriasis‐to‐eczematous switches occurred predominantly with IL‐17 and IL‐23 inhibitors, whereas AD‐to‐psoriasiform switches occurred exclusively during treatment with biologic ...
Tiago Torres, Mario Valenti, Anna Balato, Matteo Megna, Paolo Gisondi, Vimal Prajapati, Stefano Piaserico, Julia‐Tatjana Maul, Lara Valeska Maul, Jose Manuel Carrascosa, Francisco José Navarro‐Triviño, Elizabeth Lazaridou, César Ferreira, Jacopo Tartaglia, Christian Ciolfi, Athina‐Ioanna Daponte, Eugenia Veronica Di Brizzi, Maddalena Napolitano, Barbara Leal Guerra, Monica Munera‐Campos, Siddhartha Sood, Silvia Ferruci, Francesca Prignano, Esteban Dauden, Mar Llamas‐Velasco, Ron Vender, Jensen Yeung, Angelo Marzano, Luis Puig   +28 more
wiley   +1 more source

Advances in the treatment of systemic lupus erythematosus: Biologicals, small‐molecular agents, and cell‐depleting therapies coming to the clinic

Journal of Internal Medicine, EarlyView.
Abstract Systemic lupus erythematosus (SLE; lupus) remains a particular challenge for the practicing clinician on account of its chronic undulating and unpredictable course, its diverse manifestations, and—until recently—limited treatment options all associated with considerable downsides.
Ronald van Vollenhoven
wiley   +1 more source

Incidence of serious infection among etanercept and infliximab initiators: safety comparison between biosimilars and bio-originators with Canadian population-based data

BMC Rheumatology
Background Safety remains a significant concern for biologic drugs, and studies are needed to ensure a comparable safety profile for biosimilars and their legacy treatments.
Marina G. Birck, Luck Lukusa, Denis Choquette, Gilles Boire, Walter P. Maksymowych, Harminder Singh, Waqqas Afif, Sasha Bernatsky   +7 more
doaj   +1 more source

Systemic Therapy for Paediatric Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review of Current Evidence and Limitations

Journal of Paediatrics and Child Health, EarlyView.
ABSTRACT Aim The role of systemic therapy in paediatric Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) remains undefined. Management is primarily guided by observational data and variable practice patterns. This systematic review aims to integrate recent evidence and evaluate clinical outcomes associated with systemic therapies in ...
Samantha Ting, Kangjie Reuel Chua, Li‐Chuen Wong, Gloria Fong   +3 more
wiley   +1 more source

Periodontitis and Diabetes: Mechanistic Evidence of a Circular Relationship

Journal of Periodontal Research, EarlyView.
This narrative review aimed to explore the underlying mechanisms that connect periodontitis to diabetes (and vice versa) and that influence disease susceptibility, progression and response to treatment. ABSTRACT The circular relationship between periodontitis and diabetes mellitus is one of the most established oral‐systemic links.
Philip M. Preshaw, Ren Jie Jacob Chew, Charlene Enhui Goh, Ali A. Abdulkareem, Dana T. Graves   +4 more
wiley   +1 more source

Unexpected multiple sclerosis‐like symptoms in a rheumatoid arthritis patient treated with Etanercept: A case report

Clinical Case Reports
Key Clinical Massage Although tumor necrosis factor (TNF) inhibitors are used to prevent autoimmune disease, but they can cause adverse effects. Multiple sclerosis syndrome is one of the rare complications following treatment with TNF inhibitor.
Ali Hosseinpour, Arsh Haj Mohamad Ebrahim Ketabforoush, Elnaz Daneshzad, Ali Babanezhad Gajouti, Samaneh Hajimollarabi   +4 more
doaj   +1 more source